Bausch + Lomb
Clinical trials sponsored by Bausch + Lomb, explained in plain language.
An eye health company selling contact lenses, pharmaceuticals, and surgical products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye drops for pain enter early safety testing Results expected Nov 2026 (estimated)
- New laser aims to sharpen vision for the farsighted Results expected Nov 2026 (estimated)
- New eye drops aim to ease pain after laser surgery Results expected Feb 2027 (estimated)
- Can a new eye drop fully clear dry eye redness? Results expected Feb 2027 (estimated)
- New laser aims to sharpen vision for mild nearsightedness Results expected Sep 2027 (estimated)
-
Dry eye drug combo safety trial pulled before it started
Disease control CancelledThis study was designed to check the long-term safety of a new eye drop that combines two active ingredients (lifitegrast and perfluorohexyloctane) for people with dry eye disease. It was a follow-up for people who had already completed an earlier study. However, the trial was wi…
Phase 3 • Sponsor: Bausch & Lomb Incorporated • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New eye drops for pain enter early safety testing
Symptom relief OngoingThis early-stage study tests the safety of BL1332 eye drops in 24 healthy adults aged 18 to 50. Researchers will give different strengths of the drops to find the highest dose that people can tolerate without serious side effects. The goal is to see if the drops are safe enough f…
Phase 1 • Sponsor: Bausch & Lomb Incorporated • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
New laser aims to sharpen vision for the farsighted
Symptom relief OngoingThis study tests the safety and effectiveness of the TENEO 317 excimer laser used in LASIK surgery to treat farsightedness (hyperopia) with or without astigmatism. About 140 adults aged 22 and older will receive the laser treatment in one or both eyes and be followed for 12 month…
Sponsor: Bausch & Lomb Incorporated • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC